Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 16;10(9):92.
doi: 10.1038/s41408-020-00358-3.

Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib-rituximab

Massimo Gentile  1   2 , Enrica Antonia Martino  3 , Andrea Visentin  4 , Marta Coscia  5 , Gianluigi Reda  6 , Paolo Sportoletti  7 , Francesca Romana Mauro  8 , Luca Laurenti  9 , Marzia Varettoni  10 , Roberta Murru  11 , Annalisa Chiarenza  12 , Ernesto Vigna  3   13 , Francesco Mendicino  3 , Eugenio Lucia  3 , Sabrina Bossio  13 , Anna Grazia Recchia  13 , Riccardo Moia  14 , Daniela Pietrasanta  15 , Giacomo Loseto  16 , Ugo Consoli  17 , Ilaria Scortechini  18 , Francesca Maria Rossi  19 , Antonella Zucchetto  19 , Hamdi Al-Janazreh  20 , Candida Vitale  5 , Giovanni Tripepi  21 , Graziella D'Arrigo  21 , Ilaria Angeletti  22 , Riccardo Bomben  19 , Antonino Neri  6 , Giovanna Cutrona  23 , Gilberto Fronza  24 , Francesco Di Raimondo  12 , Gianluca Gaidano  14 , Antonio Cuneo  25 , Robin Foà  8 , Manlio Ferrarini  26 , Livio Trentin  4 , Valter Gattei  27 , Fortunato Morabito  28   29
Affiliations

Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib-rituximab

Massimo Gentile et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1. Overall survival of the entire population of 142 CLL patients according to SRSI.
(β2 M ≤ 5 = 0 points; β2 M > 5 = 1 point; hemoglobin > 11 g/L for women and > 12 g/L for men = 0 points; hemoglobin ≤ 11 g/L for women and ≤ 12 g/L for men = 2 points; LDH ≤ UNL = 0 points; LDH > UNL = 2 points; total score 0 = low risk; score 1–3 = intermediate risk; score 4–5 = high risk).
See this image and copyright information in PMC

References

    1. Gentile M, et al. Survival-risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A Campus CLL study. Leukemia10.1038/s41375-020-0833-x. (2020) [Epub ahead of print]. - PubMed
    1. Soumerai JD, et al. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations. Lancet Haematol. 2019;6:e366–e374. doi: 10.1016/S2352-3026(19)30085-7. - DOI - PMC - PubMed
    1. Furman RR, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 2014;370:997–1007. doi: 10.1056/NEJMoa1315226. - DOI - PMC - PubMed
    1. Sharman JP, et al. Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia. J. Clin. Oncol. 2019;37:1391–1402. doi: 10.1200/JCO.18.01460. - DOI - PMC - PubMed